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Context:Ectopic Cushing’s Syndrome (ECS) canbeadiagnostic challengewith thehormonal source
difficult to find. This study analyzes the accuracy of imaging studies in ECS localization.
EvidenceAcquisition:SystematicreviewofmedicalliteratureforECScaseseriesprovidingindividualpatient
data on at least one conventional imaging technique (computed tomography [CT]/magnetic resonance
imaging) and one of the following: 111In-pentetreotide (OCT), 131I/123I-metaiodobenzylguanidine, 18F-
fluoro-2-deoxyglucose-positronemissiontomography (FDG-PET), 18F-fluorodopa-PET (F-DOPA-PET), 68Ga-
DOTATATE-PET/CT or 68Ga-DOTATOC-PET/CT scan (68Gallium-SSTR-PET/CT).
EvidenceSummary:Theanalysis comprised231patients (females, 50.2%;age, 42.617y).Overall,
52.4%(121/231)had“overt”ECS, 18.6%had“occult”ECS, and29%had“covert”ECS. Tumorswere
located in the lung (55.3%), mediastinum-thymus (7.9%), pancreas (8.5%), adrenal glands (6.4%),
gastrointestinal tract (5.4%), thyroid (3.7%), and other sites (12.8%), and primary tumors were
mostly bronchial neuroendocrine tumors (NETs) (54.8%), pancreatic NETs (8%), mediastinum-thy-
musNETs (6.9%),gastrointestinalNETs (5.3%),pheochromocytoma (6.4%),neuroblastoma (3.2%),
andmedullary thyroidcarcinoma(3.2%).Tumorswere localizedbyCT in66.2%(137/207),magnetic
resonance imaging in 51.5% (53/103), OCT in 48.9% (84/172), FDG-PET in 51.7% (46/89), F-DOPA-
PET in 57.1% (12/21), 131/123I-metaiodobenzylguanidine in 30.8% (4/13), and 68Gallium-SSTR-
PET/CT in 81.8% (18/22) of cases. Molecular imaging discovered 79.1% (53/67) of tumors uniden-
tified by conventional radiology, with OCT the most commonly used, revealing the tumor in 64%,
followedby FDG-PET in 59.4%. F-DOPA-PETwasused inonly seven covert cases (sensitivity, 85.7%).
Notably, 68Gallium-SSTR-PET/CT had 100% sensitivity among covert cases.
Conclusions:Nuclearmedicine improves the sensitivity of conventional radiologywhen tumor site
identification is problematic. OCT offers a good availability/reliability ratio, and FDG-PET was
proven useful. 68Gallium-SSTR-PET/CT use was infrequent, despite offering the highest sensitivity.
(J Clin Endocrinol Metab 100: 3231–3244, 2015)
Ectopic Cushing’s syndrome (ECS), or ectopic ACTHsyndrome, is responsible for 10–15% of the cases of
Cushing’s syndrome. It is caused by various extrapituitary
tumors, frequently malignant. Themost prevalent tumors
associated with ECS are small cell lung carcinomas
(SCLCs) and neuroendocrine tumors (NETs), including
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syndrome; FDG, 18F-fluoro-2-deoxyglucose; F-DOPA, 18F-fluorodopa; HDDST, high-dose
dexamethasone suppression test; IPD, individual patient data; IPSS, inferior petrosal sinus
sampling; LDDST, low-dose dexamethasone suppression test; MIBG, 131I/123I-metaiodo-
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NET, neuroendocrine tumor; OCT, 111In-pentetreotide; PET, positron emission tomogra-
phy; SCLC, small cell lung carcinoma.
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bronchial carcinoids, thymic carcinoids, pancreaticNETs,
medullary thyroid carcinomas (MTCs), andpheochromo-
cytomas (1, 2). Although SCLCs are rapidly diagnosed,
the localization of other tumors can be difficult. In the
largest consecutive series, 9–27% of patients with hor-
mone tests suggesting ECS have the primary lesion not
identified even after long-term follow-up, and the condi-
tion is defined as occult ECS (1–7).
Localization of the source of ectopic ACTH secretion is
crucial. In fact, although nonmalignant conditions, such
as mediastinal lipomatosis and congenital adrenal hyper-
plasia, have been associated with ECS (8), the source of
ectopic ACTH/CRH is usually a malignant tumor (3).
Early localization and treatment can avoid surgical or
pharmacological adrenalectomy and reduce the risk of
metastatic disease (9).
The use of multiple imaging techniques with reliable,
highly sensitive procedures is recommended in most NET
guidelines (10–15), although none have specifically ad-
dressed ECS. According to guidelines of The Endocrine
Society (16), patients with Cushing’s syndrome should be
characterized by complete endocrine testing, and discor-
dant results should be handled in tertiary referral centers.
Thecombinationof thin-cutmultislice imagingwith chest,
abdominal, and pelvic computed tomography (CT) scan-
ning, plus possibly magnetic resonance imaging (MRI) of
the chest and pelvis, and complementary imaging tools,
including 111In-pentetreotide (OCT) scintigraphy, posi-
tron emission tomography (PET), and PET/CT should be
employed and possibly repeated during follow-up (6, 8).
However, the role of newmolecular imaging techniques in
localizing the source of ECS is not well established, given
the rarity ofECSand the small number of patients enrolled
in most studies.
The aim of our studywas to systematically review pub-
lished data about the diagnostic performance of simulta-
neous conventional and nuclear medicine imaging in the
identification of ectopic ACTH/CRH production, relying
on individual patient data (IPD) analysis (17). An evi-
dence-based algorithm was then developed for the use of
nuclear medicine imaging in difficult cases of ECS.
Patients and Methods
Study design
The current study is an IPD systematic review of the literature
following PRISMA guidelines. All published studies describing
single or case series of patients with ECS (ectopic ACTH- and/or
CRH-secreting tumors causingCushing’s syndrome) and report-
ing diagnostic accuracy with at least one conventional and one
nuclear medicine investigation were reviewed. A search for Eng-
lish language articles in MEDLINE, EMBASE, Cochrane Li-
brary, and SCOPUS was performed between June and Septem-
ber, 2013. Search terms were: ectopic ACTH, Cushing’s
syndrome, hypercortisolism, octreoscan, pentetreotide, MIBG,
FDG-PET, Flurodopa-PET, F-DOPA-PET, Dotatoc, Dotatate,
Dotanoc, and Gallium-PET. The search was updated in April
2015.
Study selection
Eligibility criteria included: 1) single case report; 2) case se-
ries; and 3) diagnostic studies. The review was limited to studies
published since 1995, due to the availability and standardization
of imaging techniques and tracers. Inclusion was open to all
studies published from any site (oncology, radiotherapy, radi-
ology departments) as long as the diagnosis was confirmed by
appropriate endocrine/pathology data. Reviews, editorials,
commentaries, letters and animal studies were excluded. Four
independent reviewers evaluated all titles based on the abstract;
the full text of potentially eligible articles was then analyzed. For
series not describing IPD but giving only cumulative figures, an
attempt was made to obtain the raw data from authors; other-
wise they were excluded. Supplemental Figure 1 describes the
evidence acquisition process.
Data collection and quality assessment
Four reviewers independently extracted clinical data (age,
gender, clinical status, comorbidities); basal hormonal and bio-
chemical values (plasma ACTH, serum cortisol, urinary 24-h
cortisol, serum K); response to dynamic testing with low-dose
dexamethasone suppression test (LDDST), high-dose dexameth-
asone suppression test (HDDST), CRH test, inferior petrosal
sinus sampling (IPSS); conventional radiological investigation
(CT,MRI); nuclearmedicine imaging, includingOCT, 131I/123I-
metaiodobenzylguanidine (MIBG), 18F-fluoro-2-deoxyglucose
(FDG)-PET, 18F-fluorodopa (F-DOPA)-PET, 68Ga-DOT-
ATATE-PET/CT,68Ga-DOTATOC-PET/CT, and 68Ga-DOT-
ANOC-PET/CT (the last three unitarily referred as 68Gallium-
SSTR-PET/CT); pathology (including staining for ACTH/CRH
and other neuroendocrine markers and NET grading); types of
treatment; and follow-up.
Data analysis
Analyses were performed using the IPD approach by devel-
oping a line-by-line PC-based database for statistical processing
(17). The software used for all statistical analyses was SPSS ver-
sion 17 (SPSS Inc). Data were presented as mean  SD. Loga-
rithmic transformation was applied for non-normally distrib-
uted data before analysis. Unpaired t-test was used for
comparison of tumor sizes. Sensitivity with 95% confidence in-
terval (CI) for each technique or imaging combination was cal-
culated for individual patients (not lesions). Sensitivity was de-
termined from the number of true positives and false negatives.
To test the influenceof single case reports, subgroupanalysiswas
performed comparing diagnostic accuracy in the subset of arti-
cles providing less than five cases to larger series or the entire set.
Confidence intervals for proportions were calculated according
to the Wilson score method without continuity correction (18).
Statistical significance was set at P  .05.
Results
Characteristics of the study population
A total of 1165 studies were identified as potentially
relevant. Of these, 826 were excluded based on the title
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andabstract content, and232were excludedafter full-text
analysis due to non-English language, nonhuman studies,
review, editorial, or no individual outcomes being acces-
sible. At the end of the process, 107 studies (2, 6, 19–119)
were eligible andwere included in the review (Supplemen-
tal Figure 1), for a total of 231 patients with amean age of
42.6  17 years, evenly distributed for sex (females,
50.2%).
Positive cross-sectional imaging on presentation was
reported for half of the study population (121 patients,
52.4%) (overt ECS group). In 67 patients (29%), the tu-
mor source was detected only on follow-up conventional
imagingorbynuclearmedicine functional imaging (covert
ECS group). For the remaining 43 patients (18.6%), ECS
was diagnosed on the basis of multiple biochemical tests
and clinical features, but the primary source was never
found (occult ECS group). The general characteristics of
the patients according to clinical classification are re-
ported in Table 1.
Hormonal profile and biochemical diagnosis of ECS
Mean ACTH levels were 295.6  457.1 pg/mL, with
much lower levels in occult cases (174.9  139.2 pg/mL)
than in overt cases (283  296.9 pg/mL; P  .015) and
highly variable levels in covert cases (416.2  775.9 pg/
mL). Potassium levels were similar in the three ECS cate-
gories. The response to dynamic hormonal testing is re-
ported in Table 1: 100% of patients failed to respond to
LDDSTand94.7%toHDDST; 81.4%hadno response to
CRH, whereas 92.4% showed no gradient on IPSS.
Discrepancies among tests used in the differential di-
agnosis of ECS were found in eight of 49 (16.3%) cases
when comparing HDDST against CRH: one patient re-
sponded to HDDST, seven patients responded to CRH,
and one patient responded to both HDDST and CRH but
did not show any gradient on IPSS, and the location of the
primary tumor remained unknown. Conversely, discrep-
ancies were found in 10 of 70 (14.3%) cases when com-
paring HDDST against IPSS: six responded to HDDST,
and four showed a gradient on IPSS. Finally, discrepancies
were found in seven of 28 (25%) cases when comparing
CRH against IPSS: five responded to CRH, and two
showed a gradient on IPSS. In particular, two patients
responded to CRH and showed a gradient on IPSS, but
they failed to respond to HDDST, and follow-up imaging
Table 1. Patient Characteristics According to Clinical Classification
All Overt Covert Occult
n 231 121 67 43
Size, mm 26.6  26.9 30.0  30.4 17.8  9.9 n.a.
Median (min–max) 16 (4–132) 17 (4–132) 15 (5–50)
Age, y 42.6  17.0 41.2  17.3 40  15.5 51.3  15.9
Median (min–max) 43 (3–82) 41 (3–75) 41 (9–75) 53 (20–82)
Sex
Female 108/215 (50.2%) 61/111 (55.0%) 26/62 (42.0%) 21/41 (51.2%)
Male 107/215 (49.8%) 50/111 (45.0%) 36/62 (58.0%) 20/41 (48.8%)
ACTH, pg/mL 295.6  457.1 283  296.9 416.2  775.9 174.9  139.2
Median (min–max) 172 (18.2–4425) 204 (18.2–1704) 169.5 (32–4425) 133 (25–639)
Plasma cortisol, g/dL 66.5  58.0 58.1  46.6 80  79.4 66.7  31.6
Median (min–max) 50.7 (11.5–390) 45.5 (11.5–298) 64 (21–390) 56 (22–130)
Urinary cortisol, nmol/24 h 9046.9  14 059.2 7938.6  15 754.3 11 920.2  11 586.2 8392.6  12 055.7
Median (min–max) 2946.3 (28.1–69 777) 2464 (28.1–69 777) 7515.5 (28.1–32 078) 2530.9 (189–45 747)
K, mEq/L 2.7  0.6 2.62  0.6 2.8  0.7 2.6  0.6
Median (min–max) 2.7 (1.1–3.9) 2.6 (1.8–3.8) 3.1 (1.1–3.9) 2.3 (1.8–3.9)
Staining for ACTH and/or CRH 119/137 (86.9%) 78/86 (90.7%) 39/41 (95.1%) On metastasis, 2/10
(20%)
Both ACTH and CRH 10 9 0 On metastasis, 1
Only CRH 4 3 0 On metastasis, 1
Staining for chromogranin A 55/77 (71.4%) 36/46 (78.3%) 16/24 (66.7%) On metastasis, 3/7
(42.9%)




12/73 (16.4%) 7/43 (16.3%) 5/24 (20.8%) On metastasis, 1/6
(16.7%)
LDDST (no suppression) 65/65 (100%) 37/37 (100%) 17/17 (100%) 11/11 (100%)
HDDST (no suppression) 108/114 (94.7%) 51/53 (96.2%) 31/33 (93.9%) 25/27 (92.6%)
CRH test (lack of stimulation) 48/59 (81.4%) 23/28 (82.1%) 13/16 (81.3%) 12/15 (80%)
IPSS (absence of gradient) 85/92 (92.4%) 30/34 (88.2%) 32/33 (97.0%) 22/24 (91.7%)
Abbreviations: min–max, minimum–maximum; n.a., not applicable. Data are expressed as mean  SD or number (percentage), unless stated
otherwise.
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revealed two lung nodules of 17 and 30 mm, which were
subsequently found to be positive on ACTH immuno-
staining (Table 1).Noneof theCRH-secreting tumors that
had IPSS (6/14) showed a gradient.
Tumor site and pathology
In the entire seriesof231cases, themost frequent tumor
sites were the lungs (45%), followed bymediastinum-thy-
mus (6.5%), pancreas (6.9%), adrenal glands (5.3%), and
gastrointestinal tract (4.3%). Less frequent sites were the
thyroid (3%), abdomen (2.6%), pelvis (1.3%), cranium
(5.2%), and chest (in sites other than the lungs) (1.3%).
The site of the primary tumor remained unknown in
18.6%of cases (occult ECS). Pathological typing revealed:
bronchial NET (54.8%), pancreatic NET (8%), medias-
tinum-thymusNET (6.9%), gastrointestinalNET (5.3%),
pheochromocytoma (6.4%), neuroblastoma (3.2%),
MTC (3.2%), paraganglioma (2.1%), and other histolo-
gies (10.1%). The latter included SCLCs, which were un-
derrepresented, probably because they are rapidly diag-
nosed and do not undergo nuclear imaging for source
localization or therapy. The prevalence of metastatic dis-
ease at diagnosis was 44 of 231 (19%), whereas in the
subgroup of pancreatic lesions, metastases at diagnosis
were detected in four of 16 (25%) patients, reflecting a
prevalence similar to other reports (10, 11, 13–15). Neu-
roendocrine immunostaining was available for most tu-
mors (147/231; 63.6%), with positive results on ACTH/
CRH staining in 86.9%, chromogranin A in 71.4%,
synaptophysin in 53.3%, and neuron-specific enolase in
16.4%. A total of 36.5% of ACTH-positive tumors were
also positive to chromogranin A and 22.1% to synapto-
physin. Neuroendocrine grading according to recent
guidelines (15, 120) was reported in only 14 cases, with a
relatively high prevalence of G2 (3/14; 21.4%) and G3
(2/14; 14.3%). Atypical bronchial carcinoids were re-
ported in six of 18 cases (33.3%) of bronchial carcinoids.
Sensitivity of localization techniques
The ability of conventional and nuclear medicine in-
vestigations to localize the source of ACTH is presented in
Table 2 and Supplemental Figure 2. The subgroup of pa-
tients for whom pathology was diagnostic was divided
according to clinical presentation as detected immediately
on first imaging (overtECS)ordiscovered subsequentlyon
follow-up (covert ECS). In the set of patients as a whole,
Table 2. Diagnostic Accuracy for Each Imaging Technique in All Patients, in Those With Proven Histology, and in
Overt and Covert Patients
CT MRI OCT FDG-PET F-DOPA-PET MIBG
68Gallium-SSTR-
PET/CT
All patients (n  231)
Sensitivity, % (95% CI) 66.2% (59.5–72.3) 51.5% (41.9–60.9) 48.9% (41.5–56.3) 51.7% (41.5–61.8) 57.1% (36.6–75.5) 30.8% (12.7–57.6) 81.8% (61.5–92.7)
n 137/207 53/103 84/172 46/89 12/21 4/13 18/22
True positive 63.7% 50.5% 48.3% 51.1% 54.5% 26.7% 78.3%
n 137/215 53/105 84/174 46/90 12/22 4/15 18/23
False negative 33.6% 47.6% 50.6% 47.8% 40.9% 60% 17.4%
n 70/215 50/105 88/174 43/90 9/22 9/15 4/23
False positive 3.7% 1.9% 1.1% 1.1% 4.5% 13.3% 4.3%
n 8/215 2/105 2/174 1/90 1/22 2/15 1/23
Histologically confirmed (n  188)
Sensitivity, % (95% CI) 81.1% (74.5–86.3) 73.4% (61.9–82.2) 62.9% (54.6–70.7) 65.7% (54–75.8) 65.0% (43.3–81.9) 40% (16.8–68.7) 81.8% (61.5–92.7)
n 137/169 52/71 85/135 46/70 13/20 4/10 18/22
True positive 77.4% 71.2% 62.0% 64.8% 61.9% 33.3% 78.3%
n 137/177 52/73 85/137 46/71 13/21 4/12 18/23
False negative 18.1% 26% 36.5% 33.8% 33.3% 50% 17.4%
n 32/177 19/73 50/137 24/71 7/21 6/12 4/23
False positive 4.5% 2.7% 1.5% 1.4% 4.8% 16.7% 4.3%
n 8/177 2/73 2/137 1/71 1/21 2/12 1/23
Overt (n  121)
Sensitivity % (95% CI) 98.3% (93.9–99.5) 92.9% (81.0–97.5) 63.5% (52.9–72.9) 71.1% (55.2–83) 53.9% (29.1–76.8) 37.5% (13.7–69.4) 70% (39.7–89.2)
n 113/115 39/42 54/85 27/38 7/13 3/8 9/13
True positive 97.4% 92.9% 62.1% 71.1% 50,0% 30% 69.2%
n 113/116 39/42 54/87 27/38 7/14 3/10 9/13
False negative 1.7% 7.1% 35.6% 28.9% 42.9% 50% 30.8%
n 2/116 3/42 31/87 11/38 6/14 5/10 4/13
False positive 0.9% 2.3% 7.1% 20%
n 1/116 2/87 1/14 2/10
Covert (n  67)
Sensitivity, % (95% CI) 43.6% (31.4–56.7) 44.8% (28.4–62.4) 64.0% (50.1–75.9) 59.4% (42.3–74.5) 85.7% (48.7–97.4) 50% (9.5–90.6) 100% (61–100)
n 24/55 13/29 32/50 19 /32 6/7 1/2 9/9
True positive 39.3% 41.9% 64.0% 57.6% 85.7% 50% 90.0%
n 24/61 13/31 32/50 19/33 6/7 1/2 9/10
False negative 50.8% 51.6% 36.0% 39.4% 14.3 50%
n 31/61 16/31 18/50 13/33 1/7 1/2
False positive 9.8% 6.5% 3.0% 10.0%
n 6/61 2/31 1/33 1/10
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68Ga-DOTATATE-PET/CT, 68Ga-DOTATOC-PET/CT,
and 68Ga-DOTANOC-PET/CT (unitarily referred to as
68Gallium-SSTR-PET/CT) had the highest sensitivity
(81.8%; 18/22), followed by CT (66.2%; 137/207) and
MRI (51.5%; 53/103). Considering only patients with a
histologically confirmed primary tumor, CT had the high-
est sensitivity (81.1%; 137/169), similar to 68Gallium-
SSTR-PET/CT (81.8%; 18/22), followed by MRI with a
sensitivity of 73.4% (52/71). In overt cases, CT showed
the greatest sensitivity (98.3%; 113/115), followed by
MRI (92.9%; 39/42), FDG-PET (71.1%; 27/38), 68Gal-
lium-SSTR-PET/CT (70%; 9/13), and OCT (63.5%; 54/
85). In covert cases, 68Gallium-SSTR-PET/CT showed the
greatest sensitivity (100%; 9/9), followed by F-DOPA-
PET (85.7%;6/7),OCT(64%;32/50), FDG-PET (59.4%;
19/32), MRI (44.8%; 13/29), and CT (43.6%; 24/55).
Subgroup analysis comparing the sensitivities in small or
large series is reported in Supplemental Table 1. No sig-
nificant difference was found, suggesting that the inclu-
sion of single cases had not biased the overall findings.
Analysis of false positives by localization
technique
False-positiveCTswere reported in eight of 215 (3.7%)
cases. Subsequent imaging techniques identified the true
ECS source in the following sites: four in the lung (two
identified by OCT, one by bronchoscopy, and one by F-
DOPA-PET), one para-aortic lesion (identified by OCT
and FDG-PET), one in the right atrium (identified byMRI
andFDG-PET), onewithin the thyroidgland (identifiedby
ultrasound), and one in the paranasal sinus (identified by
68Gallium-SSTR-PET/CT).
Two false-positiveMRIs were reported (2/105; 1.9%).
Subsequent imaging identified the true tumor site in the
pancreas andmediastinum lymphnodes; both lesions neg-
ative on MRI were positive on CT and OCT.
OCT had the lowest false-positive rate, with two false
uptakes (2/174; 1.1%) described in the lung hilum,
whereas the true source was an MTC identified on neck
ultrasound. This focal lesion was negative on CT and
MIBG; the patient also had small locoregional metastases
in the liver that stained positive for ACTH, calcitonin,
carcinoembryonic antigen, and synaptophysin. The other
case was a patient with an OCT-positive pancreatic NET
that, however, was not causing ECS because the true ec-
topic source was then identified in a lung NET seen at CT
scan (117).
A false-positive FDG-PET was described in one case
(1/90; 1.1%) of spleen uptake where the ACTH secretion
actually originated from a pancreatic NET positive on
ACTH staining. The lesion was retrospectively identified
by MRI, but not by CT scan.
A false-positive F-DOPA-PET was described in one
case (1/22; 4.5%) of uptake in the left ventricle, whereas
the true source was actually a 16-mm lungNET identified
by CT andMRI. This lesion was positive on ACTH stain-
ing but failed to show uptake during OCT.
A false-positive 68Gallium-SSTR-PET/CT of the adre-
nal glands was described in one case (1/23; 4.3%),
whereas the true source of ACTH was a lung NET, pos-
itive on F-DOPA-PET but not detected on CT.
Analysis of occult tumors associated with ECS
A total of 43 patients had occult ECS, in which clinical
signs and biochemical tests were suggestive of ECS but all
imaging was negative. The prevalence of occults (43/231;
18.6%; 95%CI, 14.1–24.1) in our series was comparable
to that of the five largest consecutive series (50/383;
13.1%; 95%CI, 10–16.8; P .072; data fromRef. 7). In
our series, 13 (5.6%) had partial occult ECS, defined as
subsequent identification of metastasis from an unknown
primary tumor.With regard tooccultECS,37patientshad
undergone CT; 31 patients, MRI; 39 patients, OCT; 20
patients, FDG-PET; two patients, F-DOPA-PET; and
three patients, MIBG investigation. No occult cases were
found among patients undergoing 68Gallium-SSTR-
PET/CT scan, suggesting that this approach had no false
negatives, at least in this collection of ECS patients.
Among occults, eight had undergone a pituitary surgical
exploration (26%; 8/30; if excluding the partial occults),
reducing the remote, but still possible, chance that these
patients had an invisible Cushing’s disease with biochem-
ical response typical of ECS (121).
Sensitivity according to tumor site
The ability to localize the tumor according to its pri-
mary site is reported in Table 3. Lung lesions were iden-
tified with the greatest sensitivity by CT (79.4%), 68Gal-
lium-SSTR-PET/CT (77.8%), F-DOPA-PET (71.4%),
and MRI (66.7%). Thymus-mediastinum tumors were
identified by OCT (85.7%), CT (85%), MRI (62.5%),
and FDG-PET (62.5%). Pancreatic lesions were found by
FDG-PET (100%), MRI (87.5%), and CT (85.7%). Ad-
renal gland tumors were found by CT, MRI, and FDG-
PET with a sensitivity of 100%. Gastrointestinal tract le-
sions were found by CT (90%) and MRI (71.4%).
Thyroid tumors were found by CT with a sensitivity of
80% and by OCT (66.7%). Carotid glomus, atrium, and
para-aortic region tumors were found by OCT (80%).
Head tumors were found by MRI (87.5%), OCT (80%),
and FDG-PET (71.4%). Rare abdominal sites were found
by MRI (66.7%). A detailed analysis on the combination
of various conventional and nuclear medicine imaging
techniques is described in Supplemental Table 2.
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Analysis of false positives by tumor site
In 101 lung tumors, four (4/101; 3.9%) false posi-
tives (two in the adrenal glands, one in the pancreas, and
one in the liver) were found with CT, whereas MRI and
FDG-PET did not show any false positives. In contrast,
one patient (1/83; 1.2%) showed a false OCT uptake in
the pancreas, one patient (1/15; 6.7%) showed a false
F-DOPA-PET uptake in the left ventricle, and one (1/10;
10%) showed a false 68Gallium-SSTR-PET/CT uptake
in the adrenal gland.
In thymus-mediastinum tumors, there was one false-
positive MRI finding (1/9; 11.1%), with an apparent
nodule in the left subclavicular region. In contrast, no
false positives were reported for CT, OCT, FDG-PET,
F-DOPA-PET, or 68Gallium-SSTR-PET/CT.
Among patients with proven pancreatic lesions, MRI
suggested one (1/9; 11.1%) false pituitary tumor, whereas
no false positives were described for CT, OCT, or
FDG-PET.
No false-positive CT,MRI, OCT, FDG-PET, orMIBG
findings were reported in the groups of adrenal gland tu-
mors or gastrointestinal tumors.
Among thyroid lesions, there was one false positive in
the lung with CT (1/6; 16.7%), OCT (1/4; 25%), and
MIBG (1/3; 33.3%).
In the carotid glomus, atrium, and para-aortic region,
CT showed two of five (40%) false positives with a false
uptake described in the adrenal gland and thymus,
whereas there were no false positives for MRI and OCT.
In less frequent lesions, for head tumors (ethmoidal-para-
nasal- sphenoid sinus, olfactory bulb, skull base), there
were no false positiveswithCT,MRI,OCT, or FDG-PET;
for abdominal lesions (abdominal paraganglioma, ovary),
there were no false positives with CT, MRI, or OCT.
Data on false-negative results at conventional radiol-
ogy are described in the Supplemental Data, along with
diagnostic accuracy of the combination of cross-sectional
(CT/MRI) and nuclear medicine scans (Supplemental
Table 2).
Integrated approach
Adiagnostic flowchart has been developed on the basis
of the findings collected on these 231 patients with ECS
(Figure 1) and compared to available guidelines for non-
ECS NETs (11–14, 122–125) (see Supplemental Data).
Most tumors causingECSwere in the lungs,mediastinum,
or neck. For this reason, a CT body scan was the most
useful first examination. If CT was successful in identify-
ing the lesion (137/215 in our series), OCT was found to
be the best confirmatory and the most requested exami-
nation (lowest false-positive rate). When CT and OCT
findings were concordant, most clinicians started treat-
ment, normally opting for surgery (63.1%; 65/103 in our
series). In contrast, where the OCT was negative (36.9%;
38/103), FDG-PET was the best performing third exam-
ination (36.4%). With FDG-PET confirming a previous
investigation, treatment was started. With only one pos-
itiveCT scan, clinicianswere cautious in performing treat-
Table 3. Sensitivity (95% CI) of Diagnostic Techniques in Primary Source Localization According to Tumor Site




Lung 79.4% (70.3–86.2) 66.7% (48.8–80.8) 60.9% (50.2–70.8) 54.6% (38.0–70.2) 71.4% (45.4–88.3) 50% (9.5–90.6) 77.8% (45.3–93.7)
n 77/97 20/30 50/82 18/33 10/14 1/2 7/9
Thymus, mediastinum 85% (63.9–94.8) 62.5% (30.6–86.3) 85.7% (60.1–96.0) 62.5% (30.6–86.3) 33.3% (6.2–79.2) nd 50% (15.0–85.0)
n 17/20 5/8 12/14 5/8 1/3 2/4
Pancreas 85.7% (60.1–96.0) 87.5% (52.9–97.8) 66.7% (35.4–88) 100% (61–100) nd Out of 1 case:
0 TP, 1 FN
100% (34.2–100)
n 12/14 7/8 6/9 6/6 2/2
Adrenal gland 100% (72–100) 100% (57–100) 60% (23.1–88.2) 100% (44–100) 100% (20.7–100) 50% (15–85) nd
n 10/10 5/5 3/5 3/3 1/1 2/4
Gastrointestinal tract 90% (59.6–98.2) 71.4% (35.9–91.8) 50% (21.5–78.5) 57.1% (25.1–84.2) 100% (20.7–100) nd 100% (34.2–100)
n 9/10 5/7 4/8 4/7 1/1 2/2
Thyroid 80% (37.6–96.4) 100% (20.7–100) 66.7% (20.8–93.9) 100% (43.9–100) nd Out of 3 cases:
0 TP, 1 FP, 2 FN
100% (34.2–100)
n 4/5 1/1 2/3 3/3 2/2
Carotid glomus, atrium, para-aortic
region
33.3% (6.2–79.2) 33.3% (6.2–79.2) 80% (37.6–96.4) 100% (34.2–100) nd nd nd
n 1/3 1/3 4/5 2/2
Head: ethmoidal-paranasal-sphenoid-
sinus, olfactory bulb, skull base,
etc
57.1% (25.1–84.2) 87.50% (52.9–97.8) 80% (37.6–96.4) 71.4% (35.9–91.8) Out of 1 case: 0 TP,
1 FN
nd 100% (43.9–100)
n 4/7 7/8 4/5 5/7 3/3
Abdomen/other (abdominal
paraganglioma, ovary)
60% (23.1–88.2) 66.7% (20.8–93.9) 20% (3.6–62.5) 100% (20.7–100) nd 100% (34.2–100) nd
n 3/5 2/3 1/5 1/1 2/2
Abbreviations: TP, true positive; FP, false positive; FN, false negative; nd, not done; , positive. Data are expressed as percentage (95% CI), unless
stated otherwise.
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ment (an option selected in 15.8% of cases; 34/215). An
alternative could have been to perform a highly sensitive
68Gallium-SSTR-PET/CT scan.Where CT failed to reveal
any lesion (78/215 in our series), MRI was successful in
35.3% of cases (6/17) when performed. The subsequent
confirmatory examinationwasOCT (five cases, 40%pos-
itive), whereas with both negative MRI and CT scan
(16.6%; 11/66), patients should have a 68Gallium-SSTR-
PET/CT (positive, 2/2). Most guidelines on NETs do not
indicate FDG-PET in their algorithm; however, ECS can
be sustained by aggressive pancreatic tumors or SCLC fre-
quently positive to FDG-PET. In addition, up to one-third
ofbronchial carcinoidsweredescribedwithapathologyof
atypical carcinoids. Interestingly, thyroid malignancies
(seven cases)were frequentlymissedatCTorOCT.There-
fore, if these lesionswere suspected, fine-needle aspiration
with measurement of calcitonin (or other neuroendocrine
markers) provides confirmatory findings and should be
followed by a FDG-PET scan. In addition, our analyses
also revealed that FDG-PET was more sensitive than so-
matostatin analog tracers for detection of abdominal le-
sions. Overall, the sensitivity shown by 68Gallium-SSTR-
PET/CT scans found in our collection is similar to that
reported in most recent guidelines for functioning and
nonfunctioning NETs. The herein reviewed collection of
difficult ECS cases clearly shows that two concordant ex-
ams are desirable to correctly identify the tumor source.
68Gallium-SSTR-PET/CT appears promising but is much
less available than OCT; FDG-PET use seems justified by
the higher prevalence of aggressive and/or less differenti-
ated tumors associated with ECS. For patients with un-
clear or discordant findings, a re-evaluation during fol-
low-up with a 68Gallium-SSTR-PET/CT scan could be a
reasonable add-on strategy.
Discussion
ECS has beenwell known formany decades, but it is still
a diagnostic conundrum for the clinical endocrinolo-
gist. When not overtly detected, ECS can remain undi-
agnosed due to difficulties in localizing ectopic ACTH-
secreting tumors, despite impressive advances in imaging
techniques.
Figure 1. Clinical suspicion of ectopic CS.
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The introduction of molecular imaging has greatly ex-
panded the tools for the diagnosis of neuroendocrine and
endocrine-related tumors, including those causing ECS
(11–14, 122–129). This systematic review gathers evi-
dence that helps to clarify the efficacy of nuclear medicine
imaging techniquesmost frequently used for the diagnosis
of ECS sources, highlighting their advantages and limita-
tions compared to conventional cross-sectional imaging.
Because the findings of diagnostic studies are occasionally
inflated by including patients with a clearly evident diag-
nosis, particular attention was paid to the separate anal-
ysis of data on patients with subtle or hidden disease on
presentation. In fact, this series is the largest collection of
patients with covert and occult ECS.
Clinical and hormonal characteristics
Patients were mainly diagnosed in the fourth decade of
life, with no sex differences, but wide age distribution
(130). Potassium levels do not seem to differ between the
overt and covert ECS cases. In occult cases, ACTH levels
are much lower than in the other ECS. Another point
emerging from these cases was the association of a smaller
diameter in covert ECS tumorswith a greatermeanACTH
and cortisol secretion compared to overt cases. These re-
sults suggest that covert cases need a longer workup to be
identified, meaning that they will progress muchmore be-
fore a diagnosis can be made.
In keeping with previous literature (1, 2), up to one-
fourth of patients had discordant dynamic hormonal test
results, confirming the need for multiple testing (9). In
overt tumors, HDDST was found to have a good sensi-
tivity (Table 1), confirming that no additional test was
necessary in the presence of unquestionable radiological
findings. This could also explain the underrepresentation
of SCLC inour series (seeLimitations), because SCLCsare
generally diagnosed without the need for further imaging.
Overall, HDDST performed better than in other series
(88–91%) (1, 2, 131, 132); this could have been inflated
by the stringent inclusion criteria for coverts and occults.
In contrast, IPSS was found to be the most sensitive in
covert ECS cases (97%), superior toHDDST (93.9%) and
CRH (81.3%). As expected, test performances in occult
ECS were low. Peripheral whole-body catheter venous
sampling was found to be less sensitive than CT, MRI,
scintigraphy, or PET in the localization of ACTH-produc-
ing extrapituitary tumors (2, 6, 133, 134).
Covert and occult ECS
This systematic analysis shows that whereas approxi-
mately half of ECS sources are readily diagnosed, exten-
sive investigations are needed to discover the hidden
sources in up to 30% of cases (coverts). In these patients,
nuclear imaging identified 79.1% of tumors not seen on
conventional imaging. This is an encouraging result, given
the severity of comorbidities associated with hypercorti-
solism (135, 136). However, despite intensive investiga-
tions, 18.6% of the tumor sources of ACTH remain oc-
cult, indicating the need for further improvement in
available imaging techniques. It should be highlighted,
however, that no tumor remained occult in patients who
underwent 68Gallium-SSTR-PET/CT, suggesting its pos-
sible superiority over all other imaging techniques with
which a significant number of tumors remained occult
(Table 2). 68Gallium-SSTR-PET/CT showed the highest
sensitivity in localizing covert ECS and always helped
identify its source. However, only a minority of studies
report its use (15% of coverts), indicating limited avail-
ability. The prevalence of occults in our collection was
similar to that reviewedbyEjaz et al (7) in the largest series
of consecutive patients: Ilias et al, 19% (1); Isidori et al,
14% (2); Aniszewski et al, 7% (5); Ejaz et al, 9% (7); and
Zemskova et al, 27% (6).
False-negative imaging
In identifying the tumor site where the CT was falsely
negative, MRI was helpful in 35% of cases. After false-
negative CT or MRI scans, OCT detected the source in
66.7% of cases, and subsequent FDG-PET detected it in
72.2%, suggesting that these exams could be performedas
second- and third-level investigations after a negative CT
or MRI. Where CT and OCT were both falsely negative
(six cases), FDG-PET found theACTHsource in two cases
(lung/sacrococcygeal lesion), MRI in one case (pancre-
atic), F-DOPA-PET in one case (lung), FDG-PET and F-
DOPA-PET in one case (lung), and 68Gallium-SSTR-
PET/CT in one case (sphenoid sinus).
False-positive imaging
The various discrepancies between the different di-
agnostic techniques prompted us to focus on false-pos-
itive findings. In fact, the urgent need to control severe
hypercortisolism exposes patients to the risk ofmultiple
or inconclusive surgeries when the results are inconsis-
tent (135). In this respect, OCT imaging had the lowest
false-positive rate (1.1%)—only two cases, one ofMTC
(identified on neck ultrasound) that showed a false up-
take in the lung, and one pancreatic lesion that was a
pancreatic NET coexisting with a ACTH-secreting lung
NET (identified by CT). False-positive uptakes were
described in the spleen for FDG-PET. However, FDG-
PET was particularly helpful in reducing the number of
falsely positive lungCT findings. In contrast,MIBGwas
associated with the highest percentage of false positives
(13.3%). In the much smaller group of patients who
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underwent 68Gallium-SSTR-PET/CT, there was one
false positive in the adrenal gland (whereas the true
source was a bronchial NET, negative on CT, and even-
tually identified by F-DOPA-PET). False-positive ven-
tricle uptake was described for F-DOPA-PET. The issue
of false positivity should always be taken into account
for techniques that are increasingly able to detect small
lesions. For this reason, a double-step approach is ad-
vocated, with sequential use of detection and confirma-
tory exams (Figure 1). Unique cases of the coexistence
of two distinct NETs, one secreting and the other non-
secreting (117), or different secretory activity by primary
source vs metastases and, finally, 68Gallium-SSTR-PET/CT
positivity related todegreeofhypercortisolism(113), further
complicate the scenario.
Integrated approach
None of the imaging techniques employed showed a
100% sensitivity in diagnosing lung lesions, the most fre-
quent in both overt and covert cases (9). All techniques
employed give both false-positive and false-negative re-
sults. Multiple imaging techniques are necessary for the
correct diagnosis. Site-specific differences occur, the de-
tection of thymus-mediastinum tumors being more diffi-
cult than for pancreatic lesions for which MRI and FDG-
PET appear to be highly sensitive. An approach based on
the data reviewed herein is presented in Figure 1. The
usefulness of FDG-PET in NETs has been recently re-
viewed (128). The presence of uptake on FDG-PET may
suggest that pancreatic tumors responsible for ECS have
more aggressive features than other pancreatic NETs gen-
erally considered not to be sensitive to this technique.
However, FDG-PET is very sensitive for the detection of
NETs with a proliferation index of 15% (137, 138). It
is unclear whether ACTH-secreting tumors behave more
aggressively or show poor differentiation in comparison
with other pancreatic NETs; interestingly, the current se-
ries found a relatively higher frequency of G2 and G3
compared to the other series (139). The need for multiple
investigations, including conventional imaging, FDG-
PET, and 68Gallium-SSTR-PET/CT is confirmed by a re-
cent series of seven patients with aggressive NET causing
ectopic mixed ACTH and CRH secretion (140). The role
of nuclear imaging in neuroendocrine lung lesion has been
recently meta-analyzed (141, 142). The conflicting results
with a FDG-PET detection of bronchial carcinoid ranged
from 14% to 90%, partially related to inappropriate
cutoff values given the low standardized uptake value ex-
hibited bymost carcinoids. They also found amuchhigher
detection rate and standardized uptake value in atypical
carcinoids,which inour serieswere up toone-thirdof lung
tumors.
Our study also shows that repeated imaging, in some
cases over several months, enabled the tumor source to be
identified and the condition to be resolved. However,
drugs to control adrenal function are required in cases of
severe hypercortisolism. Recent advances in old medica-
tions (143–145), the development of new drugs (43, 146,
147), and greater understanding of end-organ complica-
tions (135, 136) have made it more feasible to adopt a
watchful waiting approach for these patients, who were
previously invariably treated by bilateral adrenalectomy.
Limitations
This study presents advantages and limitations. First,
the current case series does not reflect the epidemiology of
ECS, because SCLCswere underrepresented.Most SCLCs
do not undergo nuclear imaging for source localization;
they are generally negative at octreoscan and rapidly
growing, and access to third-level procedures such as
68Gallium-SSTR-PET/CT or F-DOPA-PET is limited.
Nevertheless, the aim of the current study was not to de-
scribe the epidemiology of ECS, which only national and
international tumor registries can provide, but rather to
produce an updated analysis of all cases in which source
localization was performed using a combination of con-
ventional and nuclear imaging. Second, we systematically
included all reports matching the predefined criteria, lim-
iting reviewer selection biases; however, this approach led
to the inclusion of a significant number of single/small
series. The associated risk of bias was assessed by com-
paring small vs large published series as reported in Sup-
plemental Table 1. No major differences in sensitivities
were found.Theprevalenceof occult ECSand, conversely,
the frequency of metastatic disease at presentation were
compared to that reported for the largest ECS published
series (1, 2, 4–7) and NETs in general (11–14, 122–125,
127–129). Overall, no major differences were found, sug-
gesting that our collection was sufficiently representative
of the scenario encountered inmost referral centers.Third,
positive results are more prone to be published, and this
could have inflated the findings for newer techniques. In
this respect, however, it should be noted that inmost stud-
ies, three different imaging modalities were available for
within-subject comparisons; some studies revealed posi-
tive findings with one tracer but also negative findings
withanother tracers.Because thesenegativedatahavealso
been counted, our approach should have minimized pub-
lication bias. Finally, occult ECS is a condition that is
difficult to prove. Some patients with occult ECSmay still
have a subtle Cushing’s disease (121). However, all mea-
sures to prevent inclusion of non-ECSwere taken: we per-
formed an analysis based on IPD with extensively docu-
mented clinical and hormonal testing, pathology data (for
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100% of coverts), and negative pituitary surgical explo-
ration for one-fourth of occults.
In conclusion, this extensive collection demonstrates
the difficulty of diagnosing ECS when this is not immedi-
ately overt. However, nuclear medicine techniques may
help greatly in identifying the source of ectopic ACTH
production, with sensitivity varying according to the site.
This systematic review highlights the potentials and pit-
falls of these techniques, advocating a more reasoned use
as opposed to their random selection based on local avail-
ability.A tentative scheme, basedon the evidence gathered
in this analysis, is reported, covering an area that was not
addressed inpreviousguidelines.This is far fromdefinitive
and is limited by the retrospective nature, selection and
publication biases, and uneven number of patients who
underwent the most recent techniques. It should be em-
phasized that imaging alone, even when including molec-
ular, anatomical, biological, and endoscopic imaging, is
not sufficient for a correct diagnosis—aprocess that needs
additional information, including clinical characteristics
(128), to be integrated in a broad discussionwithin amul-
tidisciplinary team.
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